Antibody Therapy Market Size & Share 2026-2035

Antibody Therapy Market Size

The global antibody therapy market was valued at USD 317.4 billion in 2025. The market is expected to grow from USD 354 billion in 2026 to USD 1.01 trillion in 2035, at a CAGR of 12.5% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is witnessing strong expansion owing to the increasing approval and commercialization of novel antibody-based therapeutics across oncology, autoimmune disorders, infectious diseases, and neurological conditions. The growing preference for targeted biologics, coupled with advancements in monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), continues to strengthen market growth. In addition, the presence of a robust antibody pipeline and rising investments in biologics research and development are creating significant revenue opportunities for market participants. Regulatory support and the increasing number of FDA-approved antibody products are further contributing to the expansion of the antibody therapy market.

Antibody therapy refers to a targeted treatment approach that utilizes monoclonal antibody to identify and bind specific antigens associated with disease-causing cells or pathogens. These therapies are widely used in the treatment of cancer/oncology, autoimmune diseases, inflammatory disorders, and infectious diseases due to their high specificity and improved therapeutic outcomes. By selectively targeting abnormal cells while minimizing damage to healthy tissues, antibody therapies have emerged as a key component of precision medicine and next-generation biologic treatment strategies.

Major companies operating in the antibody therapy market include F. Hoffmann-La Roche, Novartis, AstraZeneca, AbbVie, Johnson & Johnson, Sanofi, Regeneron Pharmaceuticals, Bristol Myers Squibb, Eli Lilly and Company, Pfizer, and Merck & Co. These companies are actively focusing on expanding their monoclonal antibody and bispecific antibody portfolios, strengthening biologics manufacturing capabilities, and investing in AI-driven antibody discovery technologies. Strategic collaborations, licensing agreements, mergers, and acquisitions are also supporting pipeline expansion and accelerating the development of innovative targeted therapies.

From 2022 to 2024, the antibody therapy market demonstrated consistent growth driven by the increasing prevalence of chronic diseases, growing demand for personalized medicine, and rising adoption of biologics across global healthcare systems. The market expanded from approximately USD 222.3 billion in 2022 to nearly USD 281.5 billion in 2024, supported by continuous innovation in antibody engineering, favorable regulatory approvals, and expanding clinical applications. Increased healthcare expenditure, growing awareness regarding advanced biologic therapies, and the rapid advancement of next-generation antibody platforms further contributed to the market’s strong growth trajectory during the historical period.

Antibody Therapy Market Trends

• Rising demand for targeted biologic therapies has encouraged governments and major pharmaceutical companies to increase investments in research and development activities. Favorable regulatory support for the introduction of novel antibody-drug conjugates treatment is expected to accelerate market expansion. For instance, Amgen received approval from the U.S. Food and Drug Administration for Repatha (evolocumab) for the treatment of heterozygous familial hypercholesterolemia (HeFH) in patients aged 10 years and above, expanding treatment accessibility for patients suffering from this genetic condition.
• Increasing regulatory approvals and continuous launch of innovative antibody therapies are further supporting market growth. Recent approvals include antibody-drug conjugates (ADCs) for multiple cancer indications and bispecific T-cell engagers for B-cell malignancies, among others. The rising global burden of cancer and chronic diseases is significantly increasing the demand for clinically effective and targeted antibody therapies.
• The growing emphasis on biosimilar antibody development is improving treatment affordability and expanding patient access, particularly as patents for major monoclonal antibodies expire. This trend is especially beneficial in emerging economies and cost-sensitive healthcare systems, thereby supporting wider market penetration.
• The integration of artificial intelligence (AI) and machine learning technologies into antibody discovery platforms is transforming early-stage drug development by accelerating target identification, optimizing antibody engineering, and improving clinical success rates while reducing overall development timelines.
• Increasing strategic collaborations, licensing agreements, and acquisitions between established pharmaceutical companies and emerging biotechnology firms are strengthening product pipelines, enabling access to advanced technologies, and accelerating the commercialization of innovative antibody therapies globally.
• The expansion of patient-friendly delivery systems, including subcutaneous injections and long-acting formulations, is improving treatment convenience, enhancing patient adherence, and enabling the broader use of antibody therapies outside conventional hospital settings.
• Advancements in biomanufacturing technologies, such as single-use bioreactors and continuous manufacturing systems, are improving production efficiency, enhancing scalability, ensuring supply reliability, and reducing manufacturing costs associated with antibody therapies.
• Growing interest in combination treatment approaches involving antibody therapies alongside cell therapies, immune checkpoint inhibitors, and small-molecule drugs is improving therapeutic outcomes and broadening clinical applications, particularly in oncology and immune-mediated disorders.

Antibody Therapy Market Analysis

Based on the type, the antibody therapy market is segmented into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs) and other types. The monoclonal antibodies (mAbs) segment is expected to exhibit 12.7% CAGR during the forecast period.

• The dominance of the monoclonal antibodies segment is primarily attributed to the increasing utilization of mAbs in the treatment of chronic diseases such as cancer, infectious diseases, autoimmune disorders, and genetic conditions.
• Monoclonal antibodies offer highly targeted therapeutic action and generate effective immune-mediated responses, thereby improving treatment efficacy and patient outcomes.
• Furthermore, continuous advancements in recombinant biotechnology, protein engineering, recombinant DNA technology, and antibody-generation platforms are supporting the development of next-generation monoclonal antibodies, contributing significantly to segment growth.

Based on application, the antibody therapy market is segmented into oncology, autoimmune & inflammatory diseases, infectious diseases, neurological diseases and other applications. The oncology segment is poised to reach USD 516.9 billion by of 2035.

• The oncology segment dominated the market owing to the increasing adoption of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) in cancer treatment.
• The rising global prevalence of cancer and the growing demand for targeted therapies with enhanced efficacy and safety profiles are driving the adoption of antibody-based oncology therapies.
• Increased research and development investments, rapid expansion of oncology clinical pipelines, and continuous regulatory approvals for novel cancer antibodies are further supporting segment growth.
• In addition, advancements in precision medicine and biomarker-driven treatment strategies are enhancing the clinical relevance and utilization of antibody therapies in oncology care.
• Meanwhile, the infectious diseases segment is expected to witness the fastest growth during the forecast period due to the increasing focus on biologic therapies for viral and bacterial infections, growing infectious disease burden, and rising demand for rapid-acting and clinically validated antibody treatments.

Based on the source, the antibody therapy market is categorized into chimeric, murine, fully human, and humanized. The fully human segment dominated the market accounting for USD 159.3 billion in 2025.

• The fully human antibodies segment held the largest market share due to its superior safety, lower immunogenicity, and enhanced therapeutic efficacy compared to earlier antibody generations.
• These antibodies closely mimic naturally occurring human antibodies, thereby minimizing adverse immune responses and improving patient tolerance during long-term therapy.
• The extensive use of fully human antibodies across oncology, autoimmune diseases, and inflammatory disorders has significantly contributed to segment revenue growth.
• Moreover, increasing preference among regulatory authorities and healthcare professionals for safer biologic therapies is reinforcing the long-term dominance of this segment.
• In contrast, the chimeric antibodies segment is anticipated to witness the fastest growth owing to their established clinical efficacy, expanding use in oncology and infectious diseases, and continued approvals for combination therapies and niche treatment applications.

 Based on end use, the antibody therapy market is categorized into hospitals, specialty centers, and other end users. The hospitals segment held the major share of 59.9% in 2025.

• The dominance of the hospital segment is attributed to the availability of advanced healthcare infrastructure, specialized medical professionals, and sophisticated technologies required for the administration and monitoring of antibody therapies.
• Hospitals also serve as primary treatment centers for severe, chronic, and complex diseases, making them key facilities for the delivery of advanced biologic therapies and critical care services.
• The concentration of specialized treatment capabilities within hospital settings ensures effective therapy management and strengthens the segment’s leading position in the market.
• In comparison, the specialty centers segment is witnessing steady growth due to the increasing preference for specialized treatment facilities focused on complex and rare diseases that require advanced antibody-based therapeutic interventions.

North America Antibody Therapy Market

The North America market dominated the global market with a market share of 41.5% in 2025.

• The region’s market growth is driven by a strong regulatory environment, rising investments in biologics research, and increasing development of innovative antibody therapies by leading pharmaceutical and biotechnology companies. For instance, Biomedical Advanced Research and Development Authority partnered with Regeneron Pharmaceuticals under Project NextGen to support the development and regulatory advancement of next-generation COVID-19 monoclonal antibody therapies.
• The presence of major industry players, advanced healthcare infrastructure, strong reimbursement frameworks, and rapid adoption of innovative biologics further strengthen the region’s leadership in the market.
• Increasing prevalence of cancer, autoimmune disorders, and chronic inflammatory diseases across the region is also contributing to sustained demand for antibody-based therapeutics.

The U.S. antibody therapy market was valued at USD 84.6 billion and USD 94.9 billion in 2022 and 2023, respectively. The market size reached USD 120.1 billion in 2025, growing from USD 106.7 billion in 2024.

• The U.S. accounts for the highest number of approved antibody therapies globally, supported by favorable regulatory pathways such as Fast Track, Priority Review, and Breakthrough Therapy Designation programs by the U.S. Food and Drug Administration.
• The country has a strong pipeline of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), reflecting continuous innovation in targeted biologic therapies.
• High healthcare expenditure, advanced oncology treatment networks, and the widespread presence of specialty infusion centers are accelerating the adoption of premium antibody therapies across the country.
• In addition, increasing investments in AI-driven drug discovery platforms and precision medicine approaches are further supporting market growth in the U.S.

Europe Antibody Therapy Market

Europe market accounted for USD 83.8 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The market growth is supported by increasing adoption of biologic therapies, strong government support for healthcare innovation, and growing demand for targeted treatments across oncology and autoimmune disorders.
• The presence of established pharmaceutical manufacturers, favorable reimbursement systems, and expanding research activities in monoclonal antibodies and biosimilars are further contributing to regional market expansion.
• Moreover, increasing regulatory approvals for innovative antibody therapies and rising investments in biologics manufacturing capabilities are strengthening Europe’s position in the global market.

Germany dominates the Europe antibody therapy market, with strong growth potential.

• The country’s leadership is supported by advanced healthcare infrastructure, high healthcare spending, and strong adoption of precision medicine and targeted biologic therapies.
• Germany has a well-established pharmaceutical and biotechnology industry, enabling continuous development and commercialization of advanced antibody-based therapeutics.
• The increasing prevalence of cancer and autoimmune diseases, along with favorable reimbursement policies for biologics, is driving sustained market demand in the country.
• Furthermore, growing clinical research activities and collaborations between academic institutions and biopharmaceutical companies are supporting innovation in next-generation antibody therapies.

Asia Pacific Antibody Therapy Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 6.3% during the analysis timeframe.

• The regional market is driven by rapidly improving healthcare infrastructure, increasing healthcare expenditure, and growing awareness regarding targeted biologic therapies.
• Rising prevalence of cancer and chronic diseases, along with expanding access to advanced treatment options, is significantly supporting the adoption of antibody therapies across the region.
• In addition, growing investments in biotechnology research, expansion of local biologics manufacturing capabilities, and supportive government initiatives are accelerating market growth.
• Countries such as China, India, and Japan are increasingly focusing on precision medicine, AI-enabled drug discovery, and domestic biologics production, further contributing to regional expansion.

China antibody therapy market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• The country’s growth is driven by a large patient population, increasing prevalence of chronic diseases, and expanding access to advanced biologic treatments.
• Rapid expansion of domestic biotechnology companies and strategic collaborations with global pharmaceutical firms are accelerating the development of innovative antibody therapies in China.
• Government initiatives aimed at strengthening healthcare infrastructure, accelerating drug approvals, and promoting local biologics manufacturing are further supporting market growth.
• Additionally, rising healthcare awareness, growing healthcare spending, and increasing demand for precision medicine are contributing to the strong adoption of antibody therapies in the country.

Latin America Antibody Therapy Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• The market growth is supported by increasing healthcare investments, improving access to biologic therapies, and rising prevalence of chronic diseases such as cancer and autoimmune disorders.
• Growing expansion of private healthcare facilities and specialty treatment centers is improving the availability of advanced antibody therapies across the country.
• Increasing participation of multinational pharmaceutical companies through local manufacturing, partnerships, and distribution agreements is enhancing product accessibility and affordability.
• Furthermore, rising awareness regarding targeted therapies and ongoing improvements in healthcare reimbursement systems are supporting market expansion in Brazil.

Middle East and Africa Antibody Therapy Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.

• The country’s market growth is driven by increasing prevalence of chronic diseases, rising healthcare expenditure, and strong government initiatives under Vision 2030 aimed at modernizing healthcare infrastructure.
• Saudi Arabia is actively investing in advanced healthcare facilities, specialized treatment centers, and biologics manufacturing capabilities, which is creating strong demand for innovative antibody therapies.
• Increasing adoption of precision medicine, expanding access to oncology care, and rising awareness regarding targeted biologic treatments are further supporting market growth.
• Additionally, strategic collaborations with international pharmaceutical companies and ongoing healthcare reforms are expected to accelerate the availability of advanced antibody therapies across the country.

Antibody Therapy Market Share

The global market is characterized by a highly concentrated yet competitive landscape, with a limited number of multinational pharmaceutical companies accounting for a substantial portion of global revenues. F. Hoffmann‑La Roche, AbbVie, Amgen, AstraZeneca, and Johnson & Johnson collectively generate approximately 40% of the global market, supported by their strong commercialization capabilities, deep biologics expertise, and extensive global manufacturing and distribution infrastructures. These players hold dominant positions across major disease areas, including oncology, autoimmune disorders, inflammatory diseases, and hematology, driven by blockbuster monoclonal antibody (mAb) brands and well‑established clinical pipelines.

Market leadership is reinforced through continued investment in biologics R&D, lifecycle management strategies, and strategic partnerships, particularly focused on next‑generation antibody formats such as bispecific antibodies, antibody–drug conjugates (ADCs), and Fc‑engineered antibodies. Roche and AbbVie continue to expand their oncology and immunology franchises through pipeline optimization and label expansions, while companies such as Amgen and AstraZeneca are actively leveraging novel antibody platforms, biomarker‑driven development, and combination therapies to sustain competitive differentiation. Strategic acquisitions, licensing deals, and collaborations with biotechnology firms remain central to pipeline expansion, as leading players seek to address unmet clinical needs, enhance treatment specificity, and maintain long‑term revenue growth amid increasing biosimilar competition.

Antibody Therapy Market Companies

Prominent players operating in the antibody therapy industry are as mentioned below:

• AbbVie
• Amgen
• AstraZeneca
• Bristol‑Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann‑La Roche
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Seagen
• Takeda Pharmaceutical Company

 

• F. Hoffmann‑La Roche

F. Hoffmann‑La Roche holds a leading position in the global antibody therapy market, supported by its extensive and well‑established portfolio of monoclonal antibodies across oncology, immunology, and hematology. The company’s leadership is reinforced by sustained revenue generation from blockbuster antibody therapies and a strong late‑stage pipeline focusing on next‑generation formats, including bispecific antibodies and antibody–drug conjugates (ADCs). Roche continues to strengthen its market position through significant investments in biological manufacturing capacity, precision medicine, and diagnostics, demonstrating its long‑term commitment to innovation and global supply scalability.

 

• AbbVie

AbbVie is a dominant player in the antibody therapy landscape, driven primarily by its leadership in immunology and inflammation through high‑revenue monoclonal antibody brands. The company’s strong market standing is supported by lifecycle management strategies, expanded indications, and continued development of next‑generation antibodies to offset biosimilar pressure. AbbVie actively invests in R&D and strategic acquisitions to broaden its antibody pipeline, with a growing focus on hematologic malignancies and autoimmune diseases, reinforcing its long‑term growth trajectory and competitive resilience.

 

• Johnson & Johnson

Johnson & Johnson maintains a strong competitive presence in the global antibody therapy market through its diversified biologics portfolio spanning oncology, immunology, and infectious diseases. The company leverages its integrated pharmaceutical development capabilities and global commercial infrastructure to accelerate antibody innovation and market adoption. Strategic collaborations, internal platform development, and continued investment in advanced antibody technologies such as Fc‑engineered and bispecific antibodies enable Johnson & Johnson to sustain leadership while addressing evolving clinical needs across multiple therapeutic areas.

Antibody Therapy Industry News

• In March 2026, GSK completed the acquisition of RAPT Therapeutics, a California‑based clinical‑stage biopharmaceutical company focused on inflammatory and immunologic diseases. This acquisition expanded GSK’s allergy pipeline and strengthened its position in IgE‑mediated disease therapies.
• In April 2026, First Tracks Biotherapeutics debuted on the Nasdaq Global Select Market under the ticker TRAX as an independent, publicly traded clinical‑stage biotechnology company. The listing provided First Tracks Biotherapeutics with capital resources to advance its antibody development programs.
• In October 2023, AbCellera has broadened its ongoing multi-target partnership with Regeneron, aiming to identify therapeutic antibodies for up to eight targets specified by Regeneron, an increase from the initial four. This extended collaboration anticipates an expansion in the production of novel therapeutic antibodies.
• In August 2023, Tillotts Pharma and TVM Capital Life Science collaborated to establish Mage Biologics, dedicated to pioneering an innovative oral antibody therapy for ulcerative colitis. The establishment of the Mage Biologics aims in advancing humanized monoclonal antibody (mAb) for optimal potency and effectiveness, thereby strengthening its market position.

The global antibody therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 to 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Monoclonal antibodies (mAbs)
• Antibody-drug conjugates (ADCs)
• Other types

Market, By Application

• Oncology
• Autoimmune & inflammatory diseases
• Infectious diseases
• Neurological diseases
• Other applications

Market, By Source

• Chimeric
• Murine
• Fully human
• Humanized

Market, By End Use

• Hospitals
• Specialty centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE